Company news

Herantis Pharma PLC news in 2026

Herantis Pharma PLC's news releases, calls and decks from 2026, newest first.

View company

Herantis Pharma Oyj to publish financial statements for the first half of 2026 on August 20, 2026 – invitation to webcast presentation

August 10, 2026

Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer

June 25, 2026

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096

June 2, 2026

Herantis Pharma Oyj reports positive FDA feedback and finalizes Phase 2a study design for HER-096

June 2, 2026

Plc Annual Report 2025

March 30, 2026

Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases

March 16, 2026

Herantis Pharma releases 2H and FY 2025 report today

March 5, 2026

Herantis Pharma Oyj to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentation

February 23, 2026

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

February 19, 2026

Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease

January 7, 2026

Decks in 2026